

GI ReConnect

June 17-19, 2021
Napa Valley, California



Zoom Safety Block –
Delete From Slide
Master After
Formatting

Zoom Safety Block –
Delete From Slide
Master After Formatting

Disclaimer

All faculty and staff involved in the planning or presentation of continuing education activities provided by the University of Cincinnati are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

All additional planning committee members, the University of Cincinnati staff and the Gi Health Foundation staff have no relationships to disclose.

Faculty Disclosure

Darren Brenner, MD:

- Consultant, Advisor and Speaker: Allergen, Ironwood, Salix, Alpha Sigma
- Consultant and Advisor: Arena, Redhill Biopharma, Takeda, Bayer Pharmaceuticals, Alylam

Redefining the 4-5: Diagnosing IBS With a 4-5 Minute History and a Maximum 4-5 Tests

Darren M. Brenner, MD, FACG, AGAF, RFF
Associate Professor of Medicine and Surgery
Irene D. Pritzker Foundation Research Scholar
Director—Northwestern Neurogastroenterology and DGBI Programs
Northwestern University—Feinberg School of Medicine

The Problem:

- **Common Disorder**

- Affects approx. 5-8% of the USA population (Rome IV)
- 7th most common diagnosis made by PCPs in USA

- **Significant impact on quality of life**

- Life w/IBS-C/D survey (N=3254). What would exchange for 1 month of relief from IBS: >50% caffeine or alcohol, >40% sex, 24.5% cell phones, 21.5% internet for 1 month¹
- Individuals with IBS-D willing to accept >10% risk of death for cure
- International pt survey (N=1966) on ave individuals willing to give up 25% of remaining life for cure (ave loss 15 yrs)

- **Undiagnosed too often and for far to long**

- Average time to diagnosis = 4 years
- ~ 25% of individuals diagnosed with IBS-D/C received the diagnosis >5 yrs after symptoms began
- > 10% have symptoms for >10 years prior to diagnosis
- Up to 75% of IBS sufferers remain undiagnosed and this is a MAJOR problem

Palsson OS et al. Gastroenterology 2020;158:1262-1273.

Almarino C et al. DDW 2021: Abstract Su 085.

Peery AE et al. Gastroenterology 2015; 149:1731-41.

Ballou S et al. CGH 2019;17(12):2471-2478.

Shah SL et al. 2021;19(1):80-86.

Hungin APS et al. AFD 2022;11(7):1355-375.

Sayuk GS et al. AJG 2017;112:892-899.

Drossman DA et al. J Clin Gastroenterol 2009;43(6):541-550.

The Differential: Abdominal Pain and Diarrhea are Present in Many GI Conditions

Zoom Safety Block –
Delete From Slide
Master After
Formatting

	EPI	IBS-D	Celiac Disease	SIBO	Disaccharidase Deficiency	Crohn's/ Ulcerative Colitis	Giardia ²
Diarrhea	✓	✓	✓	✓	✓	✓	✓
Abdominal pain	✓	✓	✓	✓	✓	✓	✓
Bloating	✓	✓	✓	✓	✓		✓
Flatulence	✓	✓		✓	✓		✓

The overlap of symptoms can contribute to misdiagnoses as well as a delayed diagnosis of the appropriate condition^{3,4}

Zoom Safety Block –
Delete From Slide
Master After
Formatting

The IBS Pendulum

Zoom Safety Block –
Delete From Slide
Master After
Formatting



Diagnosis of exclusion^{1,2}
72% community GI
23% IBS experts

It's all IBS

Zoom Safety Block –
Delete From Slide
Master After Formatting

The Diagnostic Criteria: Rome IV*

Zoom Safety Block –
Delete From Slide
Master After
Formatting

Recurrent abdominal pain [or discomfort-deleted] **on average at least 1 day per week** in the last 3 months associated with 2 or more of the following:










**Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis*


Zoom Safety Block –
Delete From Slide
Master After Formatting

The IBS Subtypes: Rome IV

Zoom Safety Block –
Delete From Slide
Master After
Formatting

Bristol Stool Chart

Type 1		Separate hard lumps, like nuts (hard to pass)
Type 2		Sausage-shaped but lumpy
Type 3		Like a sausage but with cracks on its surface
Type 4		Like a sausage or snake, smooth and soft
Type 5		Soft blobs with clear-cut edges (passed easily)
Type 6		Fluffy pieces with ragged edges, a mushy stool
Type 7		Watery, no solid pieces. Entirely Liquid



Zoom Safety Block –
Delete From Slide
Master After Formatting

The 8 Simple “Rules” For Making An Accurate Diagnosis of IBS

Zoom Safety Block –
Delete From Slide
Master After
Formatting

1 Symptom Presentation

2 Rule Out Alarm Features*

If present* ...

Diagnostic testing
may be performed to
further evaluate patient

If none...

**Minimal testing
is necessary**

Are symptoms consistent with Rome criteria for IBS-?

- Q1. Do you experience pain?
- Q2. Does this pain improve or worsen with bowel movements?
- Q3. When the pain is present is it associated with a change in stool frequency or texture?

Are secondary causes or alarm features present?

- Q4: Is anemia or recurrent bleeding present?
- Q5: Do these symptoms represent an acute change?
- Q6: Is there a family history of Celiac, IBD, or CRC?
- Q7: Have you experienced significant unintentional weight loss?
- Q8: Did the symptoms begin after age 50?

Diagnosis based on symptoms alone potentially accurate in up to 98% of patients.

Zoom Safety Block –
Delete From Slide
Master After Formatting

The Positive Diagnostic Strategy

- 302 Pts randomized Rome III IBS no alarm signs/symptoms
 - Positive Diagnostic Strategy (CBC, CRP)
 - DOE (CBC, CRP, Ca, Bili, ALT, AP, Alb, TSH, Ttg, lactase gene, 3 O&P, flex sign + bx)
- Follow-up 4 weeks and 12 months
- Multiple Clinical and economic outcomes
 - Symptom severity compared to baseline (GSRS)
 - Symptom change from baseline
 - Satisfaction with management
 - Use of healthcare resources (practitioners, ER, further diagnostic testing, sick days)

	Baseline		4 weeks		P value ^a	1 year		P value ^a
	Diagnosis of exclusion (n = 152)	Positive diagnosis (n = 150)	Diagnosis of exclusion (n = 152)	Positive diagnosis (n = 150)		Diagnosis of exclusion (n = 152)	Positive diagnosis (n = 150)	
Gastrointestinal symptoms (GSRS-IBS/GSRS)^b								
Total score, ^c mean (SD)	3.75 (1.06)	3.70 (0.95)	3.22 (1.08)	3.21 (0.93)	.79	3.18 (1.24)	2.95 (1.87)	.17
Pain	3.96 (1.26)	3.95 (1.29)	3.47 (1.26)	3.51 (1.32)	.75	3.37 (1.45)	3.17 (1.51)	.34
Constipation	3.04 (1.70)	3.19 (1.64)	2.68 (1.48)	2.68 (1.48)	.80	2.45 (1.49)	2.54 (1.51)	.37
Diarrhea	3.53 (1.45)	3.32 (1.31)	2.89 (1.28)	2.89 (1.28)	.93	3.01 (1.47)	2.66 (1.20)	.28
Satiety	3.27 (1.80)	3.09 (1.72)	2.88 (1.63)	2.88 (1.63)	.61	2.81 (1.74)	2.54 (1.46)	.35
Bloating	4.72 (1.43)	4.76 (1.34)	4.06 (1.44)	4.06 (1.44)	.36	4.01 (1.52)	3.68 (1.61)	.38
Reflux	1.90 (1.26)	2.01 (1.20)	1.72 (1.08)	1.72 (1.08)	.28	1.76 (1.15)	1.71 (1.05)	.08
Improvement in symptoms compared with baseline, n (%)								
Better	—	—	42 (28)	47 (31)	.84	63 (41)	60 (40)	.80
Worse	—	—	24 (16)	25 (18)		13 (9)	15 (10)	
No change	—	—	78 (51)	75 (50)		44 (29)	44 (29)	
Missing	—	—	8 (5)	3 (2)		32 (21)	31 (21)	
Satisfaction with management, n (%)								
Very satisfied/satisfied	—	—	132 (87)	134 (89)	.59 ^e	104 (68)	93 (62)	.06 ^e
Dissatisfied/very dissatisfied	—	—	1	1		3 (2)	3 (2)	
Not satisfied/not dissatisfied	—	—	5 (3)	4 (3)		7 (5)	12 (8)	
Missing	—	—	14 (9)	11 (7)		38 (25)	42 (28)	

1-yr f/u total costs: \$3160 PDS \$5075 in DOE strategy P=.12

The Diagnostic Testing To Consider in Patients with Suspected IBS and No Alarm Features

Zoom Safety Block –
Delete From Slide
Master After
Formatting



IBS-D^{1,2,3}

- IgA TtG/Quantitative IgA
- Fecal calprotectin/CRP
Lactoferrin
- Serum C4/FGF-19
- SeHCAT or fecal bile acids
- When colonoscopy performed, obtain random biopsies
- Anti-CdtB/anti-vinculin antibodies

IBS-M¹

- CRP or fecal calprotectin
- IgA TtG ± quantitative IgA
- Stool diary
- Consider abdominal plain film to assess for fecal loading

IBS-C¹


- If severe or medically refractory, refer to specialist for physiologic testing

1. Chey WD et al. *JAMA*. 2015;313(9):949-958.
2. Pimentel M et al. *PLoS ONE*. 2015;10(5):e0126438.
3. Carrasco-Labra A et al. *Gastroenterology* 2019;157:859-880.


Zoom Safety Block –
Delete From Slide
Master After
Formatting

The Rule Out: Celiac Disease in IBS?

International Meta-analysis¹ Prevalence of biopsy-proven celiac disease in IBS vs controls



US Prospective Study² Non-constipated IBS patients (Rome II) biopsy-proven celiac disease





The Rule-out: IBD in IBS With Fecal calprotectin > CRP

Systematic Review: 12 studies; N=2145:1059 IBD, 595 IBS, 491 controls

Human adult studies: Pts with confirmed IBD compared ESR, CRP, Fecal Calprotectin, Fecal Lactoferrin with IBS or controls

Naive Bayes statistics to assess probability of having IBS or IBD based on biomarker values



CRP	Percent likelihood HC	Percent likelihood IBS	Percent likelihood IBD
0.1	89.9	9.8	0.2
0.2	89.8	9.9	0.3
0.3	88.4	11.2	0.4
0.4	85.8	13.6	0.6
0.5	82.1	16.8	1.1
0.6	77.4	20.8	1.8
0.7	71.7	25.8	3.0
0.8	65.1	30.2	4.7
0.9	57.9	35.0	7.2
1.0	50.2	39.3	10.6

Calprotectin	Percent likelihood HC	Percent likelihood IBS	Percent likelihood IBD
10	88.6	11.0	0.4
20	87.1	12.4	0.5
30	85.5	13.7	0.8
40	84.1	14.9	1.0
50	82.7	16.0	1.3
60	81.4	17.0	1.6
70	80.1	18.0	1.9
80	78.8	18.9	2.3
90	77.6	19.7	2.7
100	76.3	20.6	3.1

Master After Formatting

The Rule Out Even Performing Most of These: ACG Recommendations for Diagnostic Testing in IBS

Zoom Safety Block –
Delete From Slide
Master After
Formatting

Diagnostic Test	ACG Recommendation
CBC, Chemistries, Thyroid Testing	Not recommended but nobody likely to complain
Stool for ova and parasites	Not recommended*
Abdominal imaging	Not recommended
Breath testing for SIBO	Insufficient data to recommend**
Routine colonoscopy	Perform in patients with alarm features and in those aged >45
Allergy/Food sensitivity testing	Not recommended*** unless reproducible symptoms to specific food


*Giardia in individuals from or visiting endemic areas, camping, daycare exposures

**2009 recommendation

***Unless reproducible symptoms to a specific food

ty Block –
Delete From Slide
Master After Formatting


The Rule In: Breath Testing for IBS?



- Simple and safe test to diagnose SIBO
- Useful in assessing conditions associated with bloating like IBS
- Significant heterogeneity in test performance, preparation, indications for testing, and interpretation of results
- ACG IBS Guideline: Not addressed
- ACG SIBO guideline: “We **SUGGEST** the use of breath testing for the diagnosis of SIBO in patients with IBS” (conditional rec/very low level of evidence)

Updated MA: Breath Testing for SIBO in IBS

Zoom Safety Block –
Delete From Slide
Master After
Formatting



Zoom Safety Block –
Delete From Slide
Master After
Formatting

The Take Home Points:

Zoom Safety Block –
Delete From Slide
Master After
Formatting

- IBS is NOT a coverall for everything in the GI tract
 - Up to 50% of my referrals do not have IBS
- IBS is NOT a diagnosis of exclusion (unless excluding with history)
 - Earlier Rome Criteria PPV w/o alarm signs/symptoms 97-98%
- The 4-5 rule holds: Just not your mother's 4-5
 - 4-5 minutes to ask 8 questions/4-5 studies rule in and out IBS-D/0 studies for IBS-C
 - Avoid superfluous studies
- Confident positive diagnostic strategy will reduce the 75% undiagnosed threshold
- We cannot help what we cannot diagnose

Zoom Safety Block –
Delete From Slide
Master After Formatting